{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:03:32Z","timestamp":1761919412138},"reference-count":35,"publisher":"Japanese Pharmacological Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharmacol Sci"],"published-print":{"date-parts":[[2011]]},"DOI":"10.1254\/jphs.10r15fm","type":"journal-article","created":{"date-parts":[[2011,2,22]],"date-time":"2011-02-22T05:20:47Z","timestamp":1298352047000},"page":"263-269","source":"Crossref","is-referenced-by-count":11,"title":["Novel Findings for the Development of Drug Therapy for Various Liver Diseases: Genetic Variation in IL-28B Is Associated With Response to the Therapy for Chronic Hepatitis C"],"prefix":"10.1254","volume":"115","author":[{"given":"Masaya","family":"Sugiyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhito","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Mizokami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"332","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002;36:S21–S29.","DOI":"10.1053\/jhep.2002.36227"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1016\/0270-9139(95)90605-3"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Grebely J, Raffa JD, Lai C, Krajden M, Conway B, Tyndall MW. Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Can J Gastroenterol. 2007;21:447–451.","DOI":"10.1155\/2007\/796325"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.4.450"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Aborsangaya KB, Dembinski I, Khatkar S, Alphonse MP, Nickerson P, Rempel JD. Impact of aboriginal ethnicity on HCV core-induced IL-10 synthesis: interaction with IL-10 gene polymorphisms. Hepatology. 2007;45:623–630.","DOI":"10.1002\/hep.21511"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Busch MP, Glynn SA, Stramer SL, Orland J, Murphy EL, Wright DJ, et al. Correlates of hepatitis C virus (HCV) RNA negativity among HCV-seropositive blood donors. Transfusion. 2006;46:469–475.","DOI":"10.1111\/j.1537-2995.2006.00745.x"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–355.","DOI":"10.7326\/0003-4819-140-5-200403020-00010"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006;131:470–477.","DOI":"10.1053\/j.gastro.2006.06.008"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology. 2004;39:1702–1708.","DOI":"10.1002\/hep.20212"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004;350:2265–2271.","DOI":"10.1056\/NEJMoa032502"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Shiffman ML, Mihas AA, Millwala F, Sterling RK, Luketic VA, Stravitz RT, et al. Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3. Am J Gastroenterol. 2007;102:761–766.","DOI":"10.1111\/j.1572-0241.2007.01092.x"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840360730"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1159\/000086064"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Pascu M, Martus P, Hohne M, Wiedenmann B, Hopf U, Schreier E, et al. Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. Gut. 2004;53:1345–1351.","DOI":"10.1136\/gut.2003.031336"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22543"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.069674"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Gao B, Hong F, Radaeva S. Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology. 2004;39:880–890.","DOI":"10.1002\/hep.20139"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1038\/nature08463"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1038\/ng.447"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1038\/nature08309"},{"key":"23","unstructured":"23 Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138:1338–1345, 1345.e1331–e1337."},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1038\/ng.449"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808010"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2010.00671.x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003;4:69–77.","DOI":"10.1038\/ni875"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2003;4:63–68.","DOI":"10.1038\/ni873"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Siren J, Pirhonen J, Julkunen I, Matikainen S. IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29. J Immunol. 2005;174:1932–1937.","DOI":"10.4049\/jimmunol.174.4.1932"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Donnelly RP, Sheikh F, Kotenko SV, Dickensheets H. The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J Leukoc Biol. 2004;76:314–321.","DOI":"10.1189\/jlb.0204117"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. 2006;131:1887–1898.","DOI":"10.1053\/j.gastro.2006.09.052"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2005.04.004"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 O’Brien TR. Interferon-alfa, interferon-lambda and hepatitis C. Nat Genet. 2009;41:1048–1050.","DOI":"10.1038\/ng.453"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, Flamm S, et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology. 2010;52:822–832.","DOI":"10.1002\/hep.23743"},{"key":"35","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.09331SC"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T15:08:19Z","timestamp":1621436899000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/jphs\/115\/3\/115_10R15FM\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1254\/jphs.10r15fm","relation":{},"ISSN":["1347-8613","1347-8648"],"issn-type":[{"value":"1347-8613","type":"print"},{"value":"1347-8648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011]]}}}